A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol

Background: Cisplatin, a chemotherapy used to treat solid tumors, causes acute kidney injury (AKI), a known risk factor for chronic kidney disease and mortality. AKI diagnosis relies on biomarkers which are only measurable after kidney damage has occurred and functional impairment is apparent; this...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Anshika Jain, Ryan Huang, Jasmine Lee, Natasha Jawa, Yong Jin Lim, Mike Guron, Sharon Abish, Paul C. Boutros, Michael Brudno, Bruce Carleton, Geoffrey D. E. Cuvelier, Lakshman Gunaratnam, Cheryl Ho, Khosrow Adeli, Sara Kuruvilla, Giles Lajoie, Geoffrey Liu, Paul C. Nathan, Shahrad Rod Rassekh, Michael Rieder, Sushrut S. Waikar, Stephen A. Welch, Matthew A. Weir, Eric Winquist, David S. Wishart, Alexandra P. Zorzi, Tom Blydt-Hansen, Michael Zappitelli, Bradley Urquhart
Format:	article
Langue:	EN
Publié:	SAGE Publishing 2021
Sujets:	Diseases of the genitourinary system. Urology RC870-923
Accès en ligne:	https://doaj.org/article/15b7986c609a42cb8982f5a706c42a37
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

A Canadian Study of Cisplatin Metabolomics and Nephrotoxicity (ACCENT): A Clinical Research Protocol

Documents similaires